<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922465</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-109</org_study_id>
    <nct_id>NCT02922465</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effects of clopidogrel on the PK of&#xD;
      K-877 in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma exposure of K-877 by measuring Cmax when administered alone or with Clopidogrel</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma exposure of K-877 by measuring AUC when administered alone or with Clopidogrel</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of 20 participants with treatment emergent adverse events as assessed by the principle investigator</measure>
    <time_frame>Through study completion up to 17 days.</time_frame>
    <description>Subjects will be questioned in a general way by the investigator without specific symptoms suggested.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 &amp; Clopidogrel orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877</intervention_name>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>K-877 &amp; Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject provides written informed consent before any study-specific evaluation is&#xD;
             performed;&#xD;
&#xD;
          -  Subject is a healthy adult male or female volunteer between the ages of 18 and 45&#xD;
             years, inclusive at screening;&#xD;
&#xD;
          -  Subject has a BMI of 18 to 30 kg/mÂ², inclusive;&#xD;
&#xD;
          -  Subject has hematology, serum chemistry, and urinalysis test results within the&#xD;
             reference ranges, or results that do not show clinically significant abnormalities, as&#xD;
             judged by the Investigator at screening and check-in;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is a woman who is pregnant or breastfeeding;&#xD;
&#xD;
          -  Subject has clinically significant abnormalities in the screening or check-in&#xD;
             assessments;&#xD;
&#xD;
          -  Subject has current or history of clinically significant coagulation, bleeding, or&#xD;
             platelet disorders;&#xD;
&#xD;
          -  Subject or a family member of the subject has a history of coagulation or bleeding&#xD;
             disorders or reasonable suspicion of vascular malformations, including aneurysms;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

